Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AARDVARC phase II study of AZD4635 with durvalumab with or without cabazitaxel in progressive metastatic castration-resistant prostate cancer
NL-OMON51202Phase 2Withdrawn
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of imaradenant, durvalumab and cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Radiographic progression-free survival. Planned start Oct 2020; status: withdrawn.
02
Drugs
imaradenantdurvalumabcabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON51202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51202.